EQRx to Participate in the Jefferies 2022 London Healthcare Conference
EQRx, a pioneering pharmaceutical company, will present a fireside chat at the Jefferies 2022 London Healthcare Conference on November 17, 2022, at 1:30 PM GMT / 8:30 AM EST.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
EQRx, a pioneering pharmaceutical company, will present a fireside chat at the Jefferies 2022 London Healthcare Conference on November 17, 2022, at 1:30 PM GMT / 8:30 AM EST. This event highlights EQRx's commitment to providing innovative medicines at lower costs. Interested parties can access a live and archived webcast on the company's website under the News & Events section. Since its launch in January 2020, EQRx has aimed to disrupt high-cost drug categories through strategic partnerships and advanced technology.
Details
News Market Reaction – EQRX
The recorded move for EQRX in the trading session of this news was -1.09%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at substantially lower prices, today announced that management will participate in a fireside chat at the Jefferies 2022 London Healthcare Conference on Thursday, November 17, 2022, at 1:30 p.m. GMT / 8:30 a.m. EST.
A live and archived webcast of the fireside chat will be available by visiting the News & Events section of EQRx’s website, and selecting Events & Presentations, at investors.eqrx.com.
About EQRx
EQRx is a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at substantially lower prices. Launched in January 2020, EQRx is purpose-built, at scale, with a growing catalog of medicines in development in high-cost drug categories and emerging partnerships with leading payers and health systems. Leveraging cutting-edge science and technology and strategic partnerships with stakeholders from across the healthcare system, EQRx aims to provide innovative, patent-protected medicines more efficiently and cost-effectively than ever before. To learn more, visit www.eqrx.com and follow us on social media: Twitter: @EQRx_US , LinkedIn, Instagram: @eqrxinc.
EQRx™ and Remaking Medicine™ are trademarks of EQRx.
EQRx Contacts:
Media:
Dan Budwick
1AB
dan@1abmedia.com
Investors:
investors@eqrx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.